➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Merck
AstraZeneca
Johnson and Johnson

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

KORLYM Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Korlym, and what generic alternatives are available?

Korlym is a drug marketed by Corcept Therap and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in eleven countries.

The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mifepristone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Korlym

A generic version of KORLYM was approved as mifepristone by GENBIOPRO on April 11th, 2019.

  Get Started Free

Summary for KORLYM
Drug patent expirations by year for KORLYM
Recent Clinical Trials for KORLYM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Charles Drew University of Medicine and SciencePhase 2
Johns Hopkins UniversityN/A
National Institute on Alcohol Abuse and Alcoholism (NIAAA)N/A

See all KORLYM clinical trials

Paragraph IV (Patent) Challenges for KORLYM
Tradename Dosage Ingredient NDA Submissiondate
KORLYM TABLET;ORAL mifepristone 202107 2017-12-15

US Patents and Regulatory Information for KORLYM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
Medtronic
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.